NMCC - Profile

:::

林妏霙 (Wen-Ying Lin)

Return Appointment First Appointment

[簡介]

[著作]

Lin WY, Tsai CK, Yeh CM, Liu CJ. Identifying risk factors for methotrexate-induced acute kidney injury despite full prevention in patients with primary central nervous system lymphoma. Toxicol Appl Pharmacol. 2025 Jun 6;502:117436. doi: 10.1016/j.taap.2025.117436.
Ho YC, Chang MC, Lin WY, Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. J Infect Public Health. 2025 Feb 14;18(5):102705. doi: 10.1016/j.jiph.2025.102705.
Chang MC, Wu PF, Ho YC, Lin WY, Wu CY, Liu SY, Liu CJ, Lin YT. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment. J Infect Public Health. 2024 Jul;17(7):102460. doi: 10.1016/j.jiph.2024.05.048.
Lin WY, Tsai CK, Yeh CM, Chian T, Liu YC, Wang HY, Liu CJ. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. Cancer Med. 2023;12(3):3013-3026. doi: 10.1002/cam4.5215.
Wu WT*, Lin WY*, Chen YW, Lin CF, Wang HH, Wu SH, Lee YY. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. Int J Mol Sci. 2021;22(5):2404. doi: 10.3390/ijms22052404. (*Co-first author)
Lin WY, Wang HH, Chen YW, Lin CF, Fan HC, Lee YY. Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. Int J Mol Sci. 2020;21(22):8655. doi: 10.3390/ijms21228655.
Lin WY, Chen YW, Lin CF, Yang YP, Wang ML, Hung KF, Chiou SH. Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors. J Chin Med Assoc. 2020;83(8):719-724. doi: 10.1097/jcma.0000000000000358.